Interim Report Q1 2019

Summary of Q1 “The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.”

Oncopeptides Annual Report for 2018

Stockholm – 26 April 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Annual Report for 2018 now is available at the company’s website, www.oncopeptides.com and can be found under...

ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual ...

Updated financial calendar

Stockholm - April 11, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved to 28 August. The dates...

Year-end Report 2018

Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (...

Number of shares and votes in Oncopeptides

Stockholm —31 January, 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 4,750,000 shares, whi...

Oncopeptides intends to make a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...
Back to top